1. Home
  2. VTAK vs XBIO Comparison

VTAK vs XBIO Comparison

Compare VTAK & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTAK
  • XBIO
  • Stock Information
  • Founded
  • VTAK 2002
  • XBIO N/A
  • Country
  • VTAK United States
  • XBIO United States
  • Employees
  • VTAK N/A
  • XBIO N/A
  • Industry
  • VTAK Medical/Dental Instruments
  • XBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • VTAK Health Care
  • XBIO Health Care
  • Exchange
  • VTAK Nasdaq
  • XBIO Nasdaq
  • Market Cap
  • VTAK 4.1M
  • XBIO 4.4M
  • IPO Year
  • VTAK 2018
  • XBIO N/A
  • Fundamental
  • Price
  • VTAK $2.72
  • XBIO $3.91
  • Analyst Decision
  • VTAK
  • XBIO Hold
  • Analyst Count
  • VTAK 0
  • XBIO 1
  • Target Price
  • VTAK N/A
  • XBIO N/A
  • AVG Volume (30 Days)
  • VTAK 417.2K
  • XBIO 2.5M
  • Earning Date
  • VTAK 11-12-2025
  • XBIO 11-11-2025
  • Dividend Yield
  • VTAK N/A
  • XBIO N/A
  • EPS Growth
  • VTAK N/A
  • XBIO N/A
  • EPS
  • VTAK N/A
  • XBIO N/A
  • Revenue
  • VTAK $600,000.00
  • XBIO $2,446,221.00
  • Revenue This Year
  • VTAK $822.86
  • XBIO $1.99
  • Revenue Next Year
  • VTAK $168.42
  • XBIO $20.00
  • P/E Ratio
  • VTAK N/A
  • XBIO N/A
  • Revenue Growth
  • VTAK 37.62
  • XBIO N/A
  • 52 Week Low
  • VTAK $2.20
  • XBIO $2.20
  • 52 Week High
  • VTAK $20.14
  • XBIO $13.93
  • Technical
  • Relative Strength Index (RSI)
  • VTAK 55.54
  • XBIO 47.11
  • Support Level
  • VTAK $2.52
  • XBIO $2.81
  • Resistance Level
  • VTAK $2.83
  • XBIO $4.51
  • Average True Range (ATR)
  • VTAK 0.22
  • XBIO 1.15
  • MACD
  • VTAK -0.01
  • XBIO -0.22
  • Stochastic Oscillator
  • VTAK 28.99
  • XBIO 10.21

About VTAK Catheter Precision Inc.

Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.

Share on Social Networks: